NCT06951997View on ClinicalTrials.gov

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 15, 2027

Study Completion Date

December 31, 2027

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

QL1706

5mg/kg, q3w

DRUG

Chidamide

20mg, biw, q3w

DRUG

Gemcitabine

1000mg/m2 Q3W

DRUG

Nab-paclitaxel

125mg/m2 Q3W

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06951997 - QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter